Carotid intima-media thickness in spondyloarthritis patients;Espessamento da camada média-íntima da carótida em pacientes com espondiloartrite

Sao Paulo Medical Journal

Volumn 131, Issue 2, 2013, Pages 100-105

  Larocca Skare, Thelma ^a   Verceze, Guilherme Cortez ^b   de Oliveira, André Augusto ^a   Perreto, Sonia ^a  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^b School of Medicine ^*  (Brazil)

Author keywords

Ankylosing; Atherosclerosis; Carotid artery diseases; Infammation; Spondylarthropathies; Spondylitis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CHOLESTEROL; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B27 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; AGED; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BRAZIL; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DACTYLITIS; DISEASE DURATION; DOPPLER ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; SPONDYLARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL; UVEITIS;

EID: 84876957447     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-31802013000100020     Document Type: Article

References (34)

1. Goodson NJ, Symmons D P, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with infammatory polyarthritis: a ten-year followup study of primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293-2299.
2. Huang AL, Vita JA. Efects of systemic infammation on endothelium-dependent vasodilation. Trends Cardiovasc Med. 2006;16(1):15-20.
3. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(10 Suppl 1):S3-S8.
4. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1219-1223.
5. Heeneman S, Daemen MJ. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol. 2007;19(4):358-362.
6. Gonzalez-Juanatey C, Vasquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88(6):358-65.
7. Van der Horst-Bruinsma IE, Lems WF, Dijkmans BA. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S43-S49.
8. Toussirot E, Wendling D. Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Aging. 2005;22(6):451-469.
9. Toussirot E. Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, diferential diagnosis and pharmacological therapies. Drugs Aging. 2010;27(7):523-531.
10. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52(3): 174-176.
11. Choe JY, Lee MY, Rheem I, et al. No diferences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine. 2008;75(5):548-553.
12. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classifcation of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218-1227.
13. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic infammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(1):125-132.
14. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defning disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291.
15. Calin A, Garrett S, Whitelock H, et al. A new approach to defning functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-2285.
16. Torres TM, Ciconelli RM. Instrumentos de avaliação em espondilite anquilosante [Outcome measures in ankylosing spondylitis]. Rev Bras Rheumatol. 2006;46(Suppl 1):52-59.
17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modifcation of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.
18. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.
19. Kingsley G, Sieper J. Third International Workshop on Reactive Arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis. 1996;55(8):564-584.
20. Cruzat V, Cuchacovich R, Espinoza LR. Undiferentiated spondyloarthritis: recent clinical and therapeutic advances. Curr Rheumatol Rep. 2010;12(5):311-317.
21. De La Mata J, Maese J, Martinez JA, Rosario P, Loza E. Current evidence of the management of undiferentiated spondyloarthritis: a systematic literature review. Semin Arthritis Rheum. 2011;40(5):421-429, 429.e1-3.
22. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1-44.
23. Bots ML, Grobbee DE, Hofman A, Witteman JC. Common carotid intima-media thickness and risk of acute myocardial infarction: the role of lumen diameter. Stroke. 2005;36(4):762-767.
24. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14-22.
25. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002;20(2):159-169.
26. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4): 459-467.
27. Tyrrell PN, Beyene J, Feldman BM, et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010;30(5):1014-1026.
28. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stifness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47(8):1203-1207.
29. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57(6):1074-1080.
30. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37(1):161-166.
31. Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated infammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817-833.
32. Castro KR, Aikawa NE, Saad CG, et al. Infiximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol. 2011;2011:352686.
33. Spanakis E, Sidiropoulos P., Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with infammatory arthritides treated with infiximab. J Rheumatol. 2006;33(12):2440-2446.
34. Vis M, Nurmorhamed MT, Wolbink G, et al. Short term efects of infiximab on the lipid profle in patients with rheumatoid arthritis. J Rheumatol. 2005;32(2):252-255.